May 19 (Reuters) - BIOFRONTERA AG ::BIOFRONTERA ENTERS INTO FINANCE CONTRACT WITH EUROPEAN INVESTMENTBANK.EIB WILL PROVIDE A LOAN OF UP TO EUR 20 MILLION TO BIOFRONTERA-GROUP.
May 17(Reuters) - ilShinBioBase Co Ltd <068330.KQ> ::* Says it signed 600 million won contract with Il Dong Bio Science Co Ltd, to provide lyophilizer.
May 15 (Reuters) - SPRINT BIOSCIENCE AB :SIGNS A 10 YEAR RENTAL DEAL WITH HEMSÖ IN HUDDINGE.
May 11 (Reuters) - Durect Corp :Durect Corp - co and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for U.S. for posimir.Durect Corp - under terms of agreement, Sandoz will make an upfront payment to Durect of $20 million.Durect Corp - co remain's responsible for conducting persist Phase 3 trial, comparing posimir to bupivacaine HC1 after laparoscopic gall bladder removal.Durect Corp - company anticipates completing dosing patients in Q3/17 for persist Phase 3 trial and expects to have top-line data shortly thereafter.Durect - deal also includes potential for up to additional $43 million in development, regulatory milestones, up to additional $230 million in sales based milestones.
May 8 (Reuters) - ATGen <182400.KQ> ::* Says it signed a 4.05 billion won contract with Thailand company CellMark Asia Pte, to get NK Vue KIT exclusive supply right.
May 4 (Reuters) - BIOVICA INTERNATIONAL AB :BIOVICA RECEIVES ORDER WORTH ONE MILLION SEK FOR EVALUATION OF NEW CANCER DRUGS.VALUE OF ORDER IS APPROXIMATELY ONE MILLION SEK.VALUE OF ORDER IS APPROXIMATELY ONE MILLION SEK ..ORDER IS ONE OF SEVERAL FROM SAME CUSTOMER AND SO FAR, SECOND LARGEST BIOVICA HAS RECEIVED.
May 3 (Reuters) - Evolva Holding Sa :Signs two new Distributor Agreements in Europe for Veri-te .